Home / Articles / Primary Urethral Cancer

Articles

Primary Urethral Cancer

Primary Urethral Cancer: Understanding Staging, Survival Rates, and Treatment Options

Introduction

Primary urethral carcinoma is one of the rarest and most challenging cancers in urology — accounting for fewer than 1% of all urological malignancies, yet carrying survival outcomes that lag significantly behind more common cancers despite aggressive treatment. When a patient receives a staging designation like T0N2M0, the clinical implications are both specific and sobering: no detectable primary tumor at the urethral site, but regional lymph node metastases confirmed, without evidence of distant spread. Understanding what this means — for prognosis, treatment planning, and honest patient counseling — requires a clear-eyed look at the evidence.

This article explains primary urethral carcinoma from the ground up: what it is, how it is staged, what survival data tells us at each stage, and what treatment approaches the evidence supports — cutting through the complexity to deliver a trustworthy, accessible account for patients, families, and clinicians alike.

What Is Primary Urethral Carcinoma?

Anatomy and Basics

The urethra is the tube that carries urine from the bladder to the outside of the body. In men, it runs approximately 20 cm through the prostate, the urogenital diaphragm, and the penis. In women, it is approximately 4 cm long, running from the bladder neck to the external urethral meatus. Primary urethral carcinoma (PUC) arises directly from the urethral epithelium — distinct from secondary involvement of the urethra by bladder cancer or other adjacent tumors.

Primary urethral cancer is a rare but highly aggressive malignancy that causes malignant urethral obstruction. Its rarity — with an estimated incidence of fewer than 2 cases per million population per year — means that clinical experience is limited, prospective trials are essentially nonexistent, and management is largely guided by retrospective series, national database analyses, and expert consensus.

Histological Subtypes

PUC encompasses several distinct tumor types, each with different biology and prognosis:

Histological Subtype	Approximate Frequency	Predominant Gender	Predominant Location
Urothelial carcinoma (TCC)	45–55%	Male	Posterior urethra, prostatic urethra
Squamous cell carcinoma (SCC)	20–30%	Male (bulbar/anterior)	Anterior urethra in men; distal in women
Adenocarcinoma	10–25%	Female	Urethral diverticulum; proximal urethra
Clear cell adenocarcinoma	< 5%	Female	Urethral diverticulum
Other (melanoma, undifferentiated)	< 5%	Either	Variable

Significant differences in histological subtypes were observed based on gender: adenocarcinoma was more frequent in females (29.6%) compared to males (4.7%), while TCC and SCC were more common in males (48.8% and 41.9%, respectively) compared to females (25.9% and 22.2%, respectively).

Risk Factors

Identified risk factors for primary urethral carcinoma include:

Urethral stricture disease — chronic inflammation and repair processes promote malignant transformation
Recurrent urethritis — particularly chronic infection
HPV infection — human papillomavirus types 16 and 18 implicated in urethral SCC
Prior radiation to the pelvis
Urethral diverticula — particularly in women, where diverticular adenocarcinoma is well-documented
Chronic catheterization or urethrostomy

TNM Staging of Urethral Carcinoma

The Staging System

Urethral carcinoma is staged using the American Joint Committee on Cancer (AJCC) TNM classification:

T (Primary Tumor):

Ta — Non-invasive papillary, polypoid, or verrucous carcinoma
Tis — Carcinoma in situ
T1 — Tumor invades subepithelial connective tissue
T2 — Tumor invades corpus spongiosum or periurethral muscle
T3 — Tumor invades corpus cavernosum, anterior vagina, or bladder neck
T4 — Tumor invades adjacent organs (bladder, rectal wall, etc.)

N (Regional Lymph Nodes):

N0 — No regional lymph node metastasis
N1 — Single regional lymph node metastasis ≤ 2 cm
N2 — Single node > 2 cm, or multiple nodes, or bilateral nodes

M (Distant Metastasis):

M0 — No distant metastasis
M1 — Distant metastasis present

Understanding T0N2M0

The T0N2M0 designation — referenced in the Chinese donor page’s context — represents a clinically important and diagnostically challenging scenario: regional nodal metastases are present (N2), but no primary tumor is identifiable at the urethral site (T0), and there is no distant metastasis (M0).

This pattern can arise through:

Complete clinical response of the primary tumor following treatment, with residual nodal disease
Occult primary — microscopic primary tumor undetectable by current imaging
Prior incomplete resection with regional spread

Clinical nodal stage is a critical parameter for outcomes in primary urethral carcinoma. N-positive disease — whether N1 or N2 — consistently emerges as one of the most powerful independent predictors of survival across all published series.

Survival Rates: What the Data Shows

Overall Survival by Stage

The survival data for primary urethral carcinoma reflects its rarity, late presentation, and aggressive biology:

Stage Group	5-Year Overall Survival	5-Year Cancer-Specific Survival	Notes
Localized (Ta–T2, N0M0)	60–80%	75–90%	Best outcomes; surgery often curative
Locally advanced (T3–T4, N0M0)	30–50%	45–60%	Multimodal therapy required
Node-positive (any T, N+, M0)	20–35%	30–45%	N2 worse than N1
Metastatic (M1)	10–20%	15–25%	Palliative intent; median OS ~15 months

Overall survival at 5 and 10 years was 46.2% and 29.3%, respectively, whereas cancer-specific survival at 5 and 10 years was 68.0% and 60.1%, respectively in the largest SEER database analysis of male urethral cancer — spanning 2,065 men from 1988 to 2006.

The Critical Impact of Nodal Status

Across virtually every published series and database analysis, lymph node involvement is the single strongest predictor of poor outcome in urethral carcinoma:

Nodal involvement was the only prognostic factor for disease-free survival (HR: 2.03, 95% CI: 1.02–4.05, p = 0.0390).
In addition to age, grade, TNM stage, histology, and extent of surgery, nodal metastasis was a predictor of death in male urethral cancer.
Prognostic factors of worse survival in patients with primary urethral carcinoma include higher stage, grade, nodal involvement, and metastasis.

The distinction between N1 and N2 disease carries prognostic significance: multiple or bilateral lymph node involvement (N2) confers substantially worse outcomes than single-node disease (N1), though both categories are associated with significantly worse survival than node-negative disease.

Metastatic Disease: A Particularly Poor Prognosis

For metastatic patients, median overall survival was 15.2 months, and progression-free survival was 6.4 months. Among patients with distant metastatic disease (M1), treatment intent is primarily palliative — focused on maintaining quality of life and extending survival rather than cure.

Treatment Approaches

Surgery: The Foundation

For localized and locally advanced urethral carcinoma, surgery is the cornerstone of curative-intent treatment. The extent of surgery depends on tumor location, stage, and sex:

In men:

Distal urethral tumors: distal urethrectomy or partial penectomy — may preserve continence
Proximal/bulbomembranous tumors: total penectomy with perineal urethrostomy — the standard for proximal disease
High-stage disease: en bloc resection including cystoprostatectomy when bladder neck or prostate is involved

In women:

Distal tumors: local excision or anterior exenteration depending on extent
Proximal tumors: anterior pelvic exenteration — removal of bladder, urethra, and anterior vaginal wall — for T2–T4 disease

Lymph node dissection: Advanced age, black race, higher stage, grade, nodal involvement, and metastasis were all identified as prognostic factors of worse survival. Pelvic and/or inguinal lymph node dissection is performed in node-positive cases and increasingly considered in high-risk node-negative cases at experienced centers.

Multimodal Therapy for Advanced Disease

Given the poor outcomes of surgery alone in locally advanced (T3–T4) and node-positive disease, multimodal treatment combining surgery with chemotherapy and/or radiotherapy has become the standard approach at most specialized centers:

Neoadjuvant chemotherapy followed by surgery — aims to downstage bulky tumors and treat occult micrometastatic disease before definitive local therapy
Concurrent chemoradiation — an organ-preservation strategy, particularly for proximal tumors where surgery requires exenteration
Adjuvant chemotherapy or radiation — for high-risk features at pathology including positive nodes or positive surgical margins

Platinum-based regimens — primarily cisplatin plus gemcitabine (paralleling bladder cancer protocols given the urothelial histology predominance) — are most commonly used, though evidence from prospective trials is absent.

Emerging Systemic Therapies

The recognition that the majority of urethral carcinomas share histology with bladder urothelial carcinoma has opened potential application of therapies developed for bladder cancer:

Immune checkpoint inhibitors (pembrolizumab, atezolizumab) — approved for advanced urothelial carcinoma; case reports and small series document use in urethral carcinoma with PD-L1 expression
Erdafitinib — FGFR inhibitor for FGFR-altered urothelial carcinoma; potentially applicable to urethral urothelial carcinoma with FGFR mutations
Enfortumab vedotin — antibody-drug conjugate for advanced urothelial carcinoma; emerging data in urethral primaries

Prognosis Determinants: What Predicts Outcome

Beyond stage and nodal status, multiple factors independently influence survival in PUC:

Worse prognosis associated with:

Advanced age (particularly > 65 years)
Black race — a disparity requiring investigation and acknowledgment
Proximal tumor location (bulbomembranous in men, proximal in women)
Non-urothelial histology (particularly SCC and adenocarcinoma in some series)
High tumor grade
Positive surgical margins
Absence of surgery (radiation alone or systemic therapy without surgery)

Better prognosis associated with:

Distal tumor location
Lower T stage at diagnosis
Node-negative disease
Urothelial carcinoma histology
Complete surgical resection with negative margins
Multimodal treatment for locally advanced disease

Conclusion

Primary urethral carcinoma remains one of urology’s most formidable challenges — rare enough that few centers accumulate substantial experience, aggressive enough that survival at advanced stages remains poor despite multimodal treatment, and heterogeneous enough that treatment must be individualized to histology, location, sex, and stage. For patients presenting with node-positive disease (N2), honest prognostic counseling and a multidisciplinary approach are essential from the outset.

The T0N2M0 designation — nodal disease without detectable primary tumor — exemplifies the diagnostic complexity of this condition and underscores the need for specialized expertise in both imaging and surgical management.

Your next steps if you or a loved one faces a urethral carcinoma diagnosis:

Seek evaluation at a comprehensive cancer center with urological oncology expertise — surgical volume and multidisciplinary experience are critical for this rare disease
Request comprehensive molecular profiling of the tumor, particularly FGFR mutation status and PD-L1 expression, which may open targeted therapy options
Ask specifically about neoadjuvant chemotherapy before surgery for T3–T4 or N-positive disease
Sperm banking or fertility preservation discussion should occur before any treatment begins
Enquire about clinical trial eligibility — given the rarity of PUC, participation in trials is both personally and scientifically valuable
Review current EAU and NCCN guidelines on primary urethral carcinoma with your oncology team for the most current evidence-based recommendations